RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection

References

• Hoffman M, Monroe DM. Coagulation 2006: a Modern View of Hemostasis. Hematol Oncol Clin North Am. 2007;21(1):1–11. doi:10.1016/j.hoc.2006.11.004
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413–420. doi:10.1111/j.1538-7836.2008.03270.x
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu JN. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016;22:25–30. doi:10.1111/hae.13028
   PubMed Web of Science ®Google Scholar
• Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22(4):487–498. doi:10.1111/hae.13013
   PubMed Web of Science ®Google Scholar
• Khair K, Ranta S, Thomas A, Lindvall K; PedNet study group. The impact of clinical practice on the outcome of central venous access devices in children with haemophilia. Haemophilia. 2017;23(4):e276–e281. doi:10.1111/hae.13241
   PubMed Web of Science ®Google Scholar
• García-Dasí M, Aznar JA, Jiménez-Yuste V, et al. Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia. 2015;21(4):458–464. doi:10.1111/hae.12618
   PubMed Web of Science ®Google Scholar
• Osooli M, Berntorp E. Inhibitors in haemophilia: what have we learned from registries? A systematic review. J Intern Med. 2015;277(1):1–15. doi:10.1111/joim.12301
   PubMed Web of Science ®Google Scholar
• Male C, Andersson NG, Rafowicz A, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2020;106(1):123–129. doi:10.3324/haematol.2019.239160
   Web of Science ®Google Scholar
• Peyvandi F, Makris M. Inhibitor development in haemophilia. Haemophilia. 2017;23:3. doi:10.1111/hae.13145
   PubMedGoogle Scholar
• Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology. 2016;2016(1):657–662. doi:10.1182/asheducation-2016.1.657
   PubMedGoogle Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia. Haemophilia. 2020;26(S6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Young G, Liesner R, Chang T, et al. A multicenter, open-label Phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127–2138. doi:10.1182/blood.2019001869
   PubMed Web of Science ®Google Scholar
• Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137(16):2231–2242. doi:10.1182/blood.2020009217
   PubMed Web of Science ®Google Scholar
• Holstein K, Albisetti M, Bidlingmaier C, et al. Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A. Hämostaseologie. 2020;40(05):561–571. doi:10.1055/a-1127-6476
   PubMed Web of Science ®Google Scholar
• Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. 2021;138(11):923–931. doi:10.1182/blood.2019003777
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med. 2020;382(1):29–40. doi:10.1056/NEJMoa1908490
   PubMed Web of Science ®Google Scholar
• Donsante A, Miller DG, Li Y, et al. AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma. Science. 2007;317(5837):477. doi:10.1126/science.1142658
   PubMed Web of Science ®Google Scholar
• Arruda VR, Samelson-Jones BJ. Gene therapy for immune tolerance induction in hemophilia with inhibitors. J Thromb Haemost JTH. 2016;14(6):1121–1134. doi:10.1111/jth.13331
   PubMed Web of Science ®Google Scholar
• Batty P, Lillicrap D. Advances and challenges for hemophilia gene therapy. Hum Mol Genet. 2019;28(R1):R95–R101. doi:10.1093/hmg/ddz157
   PubMed Web of Science ®Google Scholar
• Monroe DM, Hoffman M. What Does It Take to Make the Perfect Clot? Arterioscler Thromb Vasc Biol. 2006;26(1):41–48. doi:10.1161/01.ATV.0000193624.28251.83
   PubMed Web of Science ®Google Scholar
• Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4(1):15. doi:10.1186/1477-9560-4-15
   PubMedGoogle Scholar
• Shetty S, Vora S, Kulkarni B, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol. 2007;138(4):541–544. doi:10.1111/j.1365-2141.2007.06693.x
   PubMed Web of Science ®Google Scholar
• Chowdary P. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: rationale with Focus on Concizumab. Drugs. 2018;78(9):881–890. doi:10.1007/s40265-018-0922-6
   PubMed Web of Science ®Google Scholar
• Aymonnier K, Kawecki C, Venisse L, et al. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia. Blood. 2019;134(19):1632–1644. doi:10.1182/blood.2019000281
   PubMed Web of Science ®Google Scholar
• Polderdijk SGI, Adams TE, Ivanciu L, Camire RM, Baglin TP, Huntington JA. Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood. 2017;129(1):105–113. doi:10.1182/blood-2016-05-718635
   PubMed Web of Science ®Google Scholar
• Barbon E, Ayme G, Mohamadi A, et al. Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Mol Med. 2020;12:4. doi:10.15252/emmm.201911298
   Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han S. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–446. doi:10.1038/s41573-019-0017-4
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. doi:10.1038/s41392-020-0207-x
   PubMed Web of Science ®Google Scholar
• Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell. 1990;2:279–289. doi:10.1105/tpc.2.4.279
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. doi:10.1038/35888
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494–498. doi:10.1038/35078107
   PubMed Web of Science ®Google Scholar
• Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci. 2001;98(17):9742–9747. doi:10.1073/pnas.171251798
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452(7187):591–597. doi:10.1038/nature06765
   PubMed Web of Science ®Google Scholar
• Barakat MR, Kaiser P. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18(5):637–646. doi:10.1517/13543780902855316
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–138. doi:10.1038/nrd2742
   PubMed Web of Science ®Google Scholar
• Maraganore J. Reflections on Alnylam. Nat Biotechnol. 2022;40(5):641–650. doi:10.1038/s41587-022-01304-3
   PubMed Web of Science ®Google Scholar
• Weng Y, Xiao H, Zhang J, Liang XJ, Huang Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37(5):801–825. doi:10.1016/j.biotechadv.2019.04.012
   PubMed Web of Science ®Google Scholar
• Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16(9):543–552. doi:10.1038/nrg3978
   PubMed Web of Science ®Google Scholar
• Safdar H, Cheung KL, Vos HL, et al. Modulation of Mouse Coagulation Gene Transcription following Acute In Vivo Delivery of Synthetic Small Interfering RNAs Targeting HNF4α and C/EBPα. PLoS One. 2012;7(6):e38104. doi:10.1371/journal.pone.0038104
   PubMed Web of Science ®Google Scholar
• Safdar H, Cheung KL, Salvatori D, et al. Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production. Blood. 2013;121(21):4413–4416. doi:10.1182/blood-2012-11-465674
   PubMed Web of Science ®Google Scholar
• Springer AD, Dowdy SF. GalNAc-siRNA Conjugates: leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018;28(3):109–118. doi:10.1089/nat.2018.0736
   PubMed Web of Science ®Google Scholar
• Sardh E, Harper P, Balwani M, et al. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019;380(6):549–558. doi:10.1056/NEJMoa1807838
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Moll S. Inherited antithrombin deficiency: a review: AT DEFICIENCY. Haemophilia. 2008;14(6):1229–1239. doi:10.1111/j.1365-2516.2008.01830.x
   PubMed Web of Science ®Google Scholar
• Lijfering WM, Brouwer JLP, Veeger NJGM, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113(21):5314–5322. doi:10.1182/blood-2008-10-184879
   PubMed Web of Science ®Google Scholar
• Croles F, Borjas-Howard J, Nasserinejad K, Leebeek F, Meijer K. Risk of Venous Thrombosis in Antithrombin Deficiency: a Systematic Review and Bayesian Meta-analysis. Semin Thromb Hemost. 2018;44(04):315–326. doi:10.1055/s-0038-1625983
   PubMedGoogle Scholar
• Escuriola Ettingshausen C, Halimeh S, Kurnik K, et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost. 2001;85(2):218–220. doi:10.1055/s-0037-1615679
   PubMed Web of Science ®Google Scholar
• Franchini M, Montagnana M, Targher G, et al. Interpatient Phenotypic Inconsistency in Severe Congenital Hemophilia: a Systematic Review of the Role of Inherited Thrombophilia. Semin Thromb Hemost. 2009;35(03):307–312. doi:10.1055/s-0029-1222609
   PubMedGoogle Scholar
• Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21(5):492–497. doi:10.1038/nm.3847
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017;377(9):819–828. doi:10.1056/NEJMoa1616569
   PubMed Web of Science ®Google Scholar
• Dargaud Y, Béguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005;93(03):475–480. doi:10.1160/TH04-10-0706
   PubMedGoogle Scholar
• Alnylam Reports Patient Death in Fitusiran Clinical Study; 2017. Available from: https://www.hemophilia.org/news/. Accessed April 1, 2023.
   Google Scholar
• Machin N, Ragni MV. An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med. 2018;9:135–140. doi:10.2147/JBM.S159297
   PubMed Web of Science ®Google Scholar
• Livnat T, Sehgal A, Qian K, et al. Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: effects of bypassing agents and antithrombin reduction. Blood Cells Mol Dis. 2020;82:102416. doi:10.1016/j.bcmd.2020.102416
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Lissitchkov T, Mamonov V, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436–1446. doi:10.1111/jth.15270
   PubMed Web of Science ®Google Scholar
• Janas MM, Schlegel MK, Harbison CE, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9(1):723. doi:10.1038/s41467-018-02989-4
   PubMedGoogle Scholar
• Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: first Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B). Blood. 2021;138(Supplement2):LBA–3. doi:10.1182/blood-2021-155018
   Google Scholar
• Young G, Srivastava A, Kavakli K, Ross C, Sathar J, Tran H. Efficacy and safety of fitusiran prophylaxis, an siRNA therapeutic, in a multicentre phase 3 study (ATLAS-INH) in people with haemophilia A or B, with inhibitors. ASH Plenary Sci Sess. 2021:543.
   Google Scholar
• Sridharan G, Liu J, Qian K, Goel V, Huang S, Akinc A. In silico modelling of the impact of antithrombin lowering on thrombin generation in rare bleeding disorders. Blood. 2017;130(Supplement 1):3659.
   Google Scholar
• Ten Kate MK, Van Der Meer J. Protein S deficiency: a clinical perspective. Haemophilia. 2008;080512004759292. doi:10.1111/j.1365-2516.2008.01775.x
   Web of Science ®Google Scholar
• Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci. 2006;103(9):3106–3111. doi:10.1073/pnas.0504240103
   PubMed Web of Science ®Google Scholar
• Mahasandana C, Veerakul G, Tanphaichitr VS, Suvatte V, Opartkiattikul N, Hathaway WE. Homozygous protein S deficiency: 7-year follow-up. Thromb Haemost. 1996;76(6):1122. doi:10.1055/s-0038-1650718
   PubMed Web of Science ®Google Scholar
• Prince R, Bologna L, Manetti M, et al. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood. 2018;131(12):1360–1371. doi:10.1182/blood-2017-09-800326
   PubMed Web of Science ®Google Scholar
• Prince R, Schaeper U, Dames S, et al. Targeting Protein S Using Small Interfering RNA Is Well Tolerated and Protects Mice with Hemophilia a from Acute Hemarthrosis. ASH Oral Abstr. 2020:54.
   Google Scholar
• Tollefsen DM. Heparin Cofactor II Modulates the Response to Vascular Injury. Arterioscler Thromb Vasc Biol. 2007;27(3):454–460. doi:10.1161/01.ATV.0000256471.22437.88
   PubMed Web of Science ®Google Scholar
• Rau J, Mitchell J, Fortenberry Y, Church F. Heparin Cofactor II: discovery, Properties, and Role in Controlling Vascular Homeostasis. Semin Thromb Hemost. 2011;37(04):339–348. doi:10.1055/s-0031-1276582
   PubMedGoogle Scholar
• Lopaciuk S, Bykowska K, Kopeć M. Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis. Pol J Pharmacol. 1996;48(1):109–111.
   PubMedGoogle Scholar
• Tollefsen DM. Heparin Cofactor II Deficiency. Arch Pathol Lab Med. 2002;126(11):1394–1400. doi:10.5858/2002-126-1394-HCID
   PubMed Web of Science ®Google Scholar
• Lin W, Zhu R, Zhang Z, et al. RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A. Mol Ther Nucleic Acids. 2021;24:658–668. doi:10.1016/j.omtn.2021.03.022
   PubMedGoogle Scholar
• Kempton CL, Makris M, Holme PA. Management of comorbidities in haemophilia. Haemophilia. 2021;27(S3):37–45. doi:10.1111/hae.14013
   PubMedGoogle Scholar
• Ridker PM. Ethnic Distribution of Factor V Leiden in 4047 Men and Women: implications for Venous Thromboembolism Screening. JAMA. 1997;277(16):1305. doi:10.1001/jama.1997.03540400055031
   PubMed Web of Science ®Google Scholar
• Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. The Lancet. 1995;346(8983):1133–1134. doi:10.1016/S0140-6736(95)
   PubMed Web of Science ®Google Scholar
• Pipe S, Srivastava A, Klamroth R, et al. Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B Without inhibitors [abstract]. ISTH Congr. 2022.
   Google Scholar
• Philipp C. The Aging Patient with Hemophilia: complications, Comorbidities, and Management Issues. Hematology. 2010;2010(1):191–196. doi:10.1182/asheducation-2010.1.191
   PubMedGoogle Scholar
• Pierce GF, Haffar A, Ampartzidis G, et al. First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries. Haemophilia. 2018;24(2):229–235. doi:10.1111/hae.13409
   PubMed Web of Science ®Google Scholar
• Andersson NG, Auerswald G, Barnes C, et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - The impact of prophylactic treatment. Br J Haematol. 2017;179(2):298–307. doi:10.1111/bjh.14844
   PubMed Web of Science ®Google Scholar
• Krumb E, Hermans C. Living with a “hemophilia‐free mind” – the new ambition of hemophilia care? Res Pract Thromb Haemost. 2021;5(5):e12567. doi:10.1002/rth2.12567
   PubMed Web of Science ®Google Scholar